The Fall of Elizabeth Holmes: Theranos and Leadership Lessons

In the fast-paced world of Silicon Valley, innovation is revered, and the next big idea often promises to change everything. But for every success story, there's a cautionary tale—a reminder of the risks that come with ambition and the perils of cutting corners. One of the most infamous stories in recent years is that of Theranos, the blood-testing startup founded by Elizabeth Holmes. What began as a vision to revolutionize healthcare quickly spiraled into one of the biggest scandals in business history. Elizabeth Holmes, once hailed as the next Steve Jobs, now stands as a cautionary symbol of how leadership, overconfidence, and a lack of transparency can lead to disastrous outcomes. How did Theranos go from Silicon Valley darling to a cautionary tale of fraud?

Let’s take a deeper look at the rise and fall of this once-promising company.

But before that, a few too many words about the sponsor.

Accomplish More. Juggle Less.

Your business is growing, and so are your responsibilities. So what do you do?

You do more.

You see a chance to expand your reach and increase your impact.

You do more.

You take on more hours, juggle more deadlines, and wear more hats. You miss a ball game here and there. Come home late a few more nights. You spend a holiday or two in your inbox. And you tell yourself,

This season just requires more.

But what if growing your business isn’t about doing more things — but instead doing the right things?

What if you could enjoy the holidays this year knowing that someone else is handling the “more”?

Your time is too valuable to waste. BELAY’s flexible staffing solutions can help.

Whether it’s administrative, accounting, or marketing support that you need, BELAY’s highly vetted professionals have the more you’re looking for.

Our exceptional Virtual Assistants, Accounting Professionals, and Marketing Assistants combine AI tools with extensive industry experience to ensure that you are always getting more without sacrificing quality or time.

Accomplish more and juggle less with BELAY.

Learn how with our free ebook, Delegate to Elevate, and leave the “more” to BELAY.

Download now

The Beginnings

Theranos, founded in 2003 by 19-year-old Elizabeth Holmes, emerged with the ambitious goal of revolutionizing blood testing. Holmes, a chemical and electrical engineering student at Stanford University, conceived the idea of developing a wearable patch capable of adjusting drug dosages and notifying doctors of changes in patients' blood. Motivated by a personal fear of needles, she envisioned creating lab-on-a-chip technology that would enable comprehensive blood tests using minimal amounts of blood, thereby making diagnostics more accessible and affordable.

To pursue this vision, Holmes left Stanford and utilized her parents' education trust to establish a company initially named "Real-Time Cures." She later rebranded it as "Theranos," a portmanteau of "therapy" and "diagnosis," to avoid skepticism associated with the word "cure." Holmes's determination and persuasive abilities attracted early support, notably from Channing Robertson, her advisor and dean at Stanford's School of Engineering, who became the company's first board member and introduced her to venture capitalists.

A short very successful stint

Theranos had a strong start in its early years, during which the company gained significant momentum and secured substantial funding to support its upcoming R&D and company-building efforts. Here is how the journey looks like:

• 2004: Early Funding and Company Valuation: Theranos raised $6.9 million in its first significant round of funding. The investment valued the startup at approximately $30 million. The funding reflected the early investor’s confidence in Holmes's vision, despite the lack of peer-reviewed research or public demonstrations of the technology.

• 2007: Significant Investment and Growth: Theranos raised an additional $43.2 million, bringing its valuation to $197 million. The company operated largely in stealth mode, with little information disclosed about its technology or operations. Holmes continued to attract high-profile investors with her charismatic leadership and promised of disruptive innovation. Internal reports, however, suggested that the company's proprietary technology, dubbed as "Edison machine," struggled to deliver accurate and reliable test results. Ouch…

• 2010: Reaching Unicorn Status: The company achieved a $1 billion valuation, earning the coveted "unicorn" startup status in Silicon Valley. Elizabeth Holmes became a rising star in the tech and healthcare industries, with many comparing her to Steve Jobs. Theranos continued to promise ground-breaking advancements in blood testing, while questions about the technology's viability remained largely unaddressed.

• 2013: Strategic Partnerships and Public Emergence: Theranos announced a partnership with Walgreens, one of the largest pharmacy chains in the U.S. The plan involved setting up "Wellness Centers" in Walgreens stores, where patients could get blood tests using Theranos’ technology. This partnership marked Theranos' official emergence from stealth mode and drew significant public attention. Holmes began extensive media appearances, promising affordable and accessible healthcare diagnostics for all.

• 2014: Peak Valuation and Media Spotlight: Theranos raised over $400 million in venture capital, pushing its valuation to a whooping $9 billion. According to Forbes, Elizabeth Holmes became the youngest self-made female billionaire in the world, with a personal net worth of approximately $4.5 billion. She appeared on the covers of major magazines such as Fortune, Forbes, and Glamour, being hailed as the face of a healthcare revolution. Theranos boasted a prestigious board of directors, including former U.S. Secretary of State George Shultz, former Secretary of Defense William Perry, and former U.S. Senator Sam Nunn. Despite the fanfare, concerns began to emerge internally and also among medical experts regarding the reliability of the company's blood-testing technology.

• 2015: Regulatory Milestones and Early Skepticism: Theranos received FDA approval for its HSV-1 test (herpes simplex virus 1), marking the first and only test to receive such approval out of the 200 tests the company claimed to offer. While Theranos framed this as a major achievement, regulatory agencies such as the FDA and Centers for Medicare & Medicaid Services (CMS) begin scrutinizing the company’s lab practices and testing methods. Investigative journalists, including John Carreyrou of The Wall Street Journal, started probing into the discrepancies between Theranos’s public claims and its technological capabilities.

With this specter of development looming in the background, things took a turn for the worse in 2015. The discrepancies proved far worse than they seem, and Holmes seems to be in far more trouble than she looked as well.

The Trials and Eventual Fall

This early early skepticism led the way to something bigger. Before the Holmes trial took place, there was an exposé by John Carreyrou. This led to ABC’s 2019 podcast called The Dropout, and Alex Gibney’s 2019 documentary called The Inventor: Out for Blood in Silicon Valley. And finally before the public backlashed, there was more to the case.

• 2015: The Cracks Begin to Show - The Wall Street Journal Investigation
  In October 2015, Wall Street Journal journalist John Carreyrou published a groundbreaking article that exposed Theranos's technology as unreliable and flawed. Carreyrou revealed that the "Edison" machines—Theranos's flagship technology—could not deliver accurate test results for most of the tests they claimed to run. Instead of using their own technology, Theranos was secretly using commercial devices from traditional blood-testing companies like Siemens to run tests, diluting small blood samples to work with these machines, which often led to inaccurate results. Carreyrou's sources included former employees and whistleblowers, notably Tyler Shultz (grandson of board member George Shultz) and Erika Cheung, who flagged ethical and scientific concerns.

The FDA (Food and Drug Administration) conducted an inspection of Theranos labs and concluded that the Edison device was not capable of performing the wide array of tests as claimed. The FDA determined that Theranos was using unapproved methods for patient testing and had not validated the accuracy of its results. The HSV-1 test, the only FDA-approved test by Theranos, became the company's primary shield against criticism.

Theranos had been running "Wellness Centers" in Walgreens stores, but by late 2015, Walgreens halted its plans for further expansion. Walgreens started an internal review of its partnership with Theranos after patient complaints and regulatory warnings.

• 2016: Regulatory Backlash and Collapse Begins - CMS Investigation and Sanctions
  In January 2016, the Centers for Medicare & Medicaid Services (CMS) released a scathing report detailing major deficiencies in Theranos' Newark, California lab. CMS determined that Theranos’ laboratory practices posed an "immediate jeopardy to patient health and safety." By July 2016, CMS revoked Theranos' license to operate its Newark lab and banned Elizabeth Holmes from owning or operating a lab for two years.

  In June 2016, Walgreens officially terminated its partnership with Theranos and closed all remaining Wellness Centers. Walgreens also sued Theranos, seeking $140 million in damages for breach of contract and fraud.

  Investors, patients, and partners filed lawsuits against Theranos for fraud and misrepresentation. The SEC (Securities and Exchange Commission) also began investigating Theranos for potential securities fraud, focusing on whether investors were misled about the company’s technology and financial health.

• 2017: Theranos Faces the SEC and Legal Pressure
  In March 2017, Theranos settled with the Centers for Medicare and Medicaid Services (CMS) by agreeing to shut down its labs and focus on developing new technology. The SEC found evidence suggesting that Theranos had exaggerated its financial projections, claiming revenue of $100 million in 2014, when the actual revenue was closer to $100,000.

  Theranos settled multiple lawsuits with prominent investors, including Partner Fund Management, which had invested $96 million. By 2017, Theranos had also begun laying off hundreds of employees as the company struggled to stay afloat financially.

  Theranos had been on the wrong side of a few things—they had promoted wrong messages, promising erroneous claims, there was laboratory mismanagement, financial mismanagement, and an overall disregard for stakeholders. Theranos hadn’t been aware of what they were dealing with, and neither did they have a clear vision as to what was going to happen.

The Current Status

What proceeded post-2017 was the shutting down of Theranos in 2018. But that wasn’t it. There were major charges levied on Holmes and her erstwhile romantic partner, Sunny Balwani. Holmes and Balwani were both sent to prison. Some highlights of the trial proceedings are given below.

• June 2018, Indictment of Elizabeth Holmes and Ramesh "Sunny" Balwani: A federal grand jury indicted Elizabeth Holmes and former Theranos president Ramesh "Sunny" Balwani on multiple counts of wire fraud and conspiracy to commit wire fraud. The charges alleged that they engaged in a multi-million-dollar scheme to defraud investors, doctors, and patients by making false claims about Theranos's blood-testing technology.

• September 2018, Dissolution of Theranos: Theranos announces its dissolution. The company, once valued at $9 billion, ceases operations and began processing the remaining cash and assets to creditors.

• March 2021, Trial Postponement: Elizabeth Holmes's criminal trial, initially set for July 2020, is further delayed due to the COVID-19 pandemic and Holmes's pregnancy. The trial got rescheduled to commence in August 2021.

• September 2021, Commencement of Trial: The highly anticipated trial of Elizabeth Holmes began in San Jose, California. Prosecutors argued that Holmes intentionally deceived investors and patients about the capabilities of Theranos's technology, while the defense contended that she acted in good faith and was unaware of the technology's flaws.

• November 2021, Holmes Testifies in Court: Elizabeth Holmes took the stand in her own defense, claiming she did not knowingly mislead anyone and that she believed in Theranos's technology until the very end.

• January 2022, Verdict and Conviction: After several months of deliberation, Elizabeth Holmes was found guilty on four counts of fraud and conspiracy, while she was acquitted on several other counts. She faced up to 20 years in prison for each count, with sentencing scheduled for later that year.

The Takeaways and What Went Wrong

What can entrepreneurs, investors, and startup enthusiasts learn from this cautionary tale?

• The Dangers of Overpromising and Underdelivering: Theranos represents a prime example of the perils of overpromising and underdelivering. Holmes presented a visionary yet ultimately impractical solution to a real problem, but her inability to deliver on her promises led to the company's collapse.

• Due Diligence and Trust: Investors, journalists, and customers failed to ask the right questions about Theranos' technology. The charismatic founder, combined with a prestigious board of directors and a slick PR campaign, created a facade of credibility that overshadowed the actual performance of the company.

• The Role of Integrity in Leadership: Holmes's ambition clouded her judgment. By surrounding herself with high-profile individuals and leveraging her persuasive abilities, she built a company around a false narrative. This story underscores the importance of ethics and transparency in leadership.

• The Need for Scientific Rigor and Accountability: Theranos lacked the scientific rigor necessary to validate its technology. The company’s reluctance to subject its technology to peer-reviewed scrutiny, along with its secretive and manipulative approach, ultimately sealed its fate.

In conclusion, the Theranos saga serves as a sobering reminder that leadership requires more than charisma and big ideas. It requires a commitment to truth, transparency, and accountability. Entrepreneurs and investors must remember that no amount of charm can replace the foundational work necessary to build a truly innovative and sustainable business.

About the Writer: Janakiraman S is a passionate business enthusiast with a knack for storytelling. Hailing from Chennai, he completed his schooling at The School KFI and earned his undergraduate degree from SRM Institute of Science and Technology. Currently pursuing an MBA in International Business at T. A. Pai Management Institute (TAPMI), Janakiraman is focused on broadening his horizons and setting ambitious goals for the future.

This brings us to the end of another story, a truly exceptional one in my opinion. I really hope you liked it. If you did, share this within your network and if you haven’t subscribed to Think Tank already, do it using the link below.

I will get back to you with more stories like these. In the meantime, take a look at these other interesting case studies:

• Micromax: From Dominance to Decline and the Road to Revival?

• Tupper-where?

• Vishal mega mart: Going big in retail

Keep tuned for more such case studies.
Until then,
Happy Reading!